Specific usage and dosage reference of Platinib

Pralsetinib (Pralsetinib) is a targeted therapy drug, a receptor tyrosine kinase inhibitor (TKI), used to treat RETgene fusion-positive non-small cell lung cancer (NSCLC) and other RET mutation-related tumors, such as thyroid cancer. As a targeted drug, Platinib plays an anti-cancer role by specifically inhibiting the activity of RET receptor tyrosine kinase and preventing the growth and spread of tumor cells.

The standard use of platinib is by mouth, usually in capsule form. The recommended starting dose for adult patients is 400 mg once daily, preferably at the same time. Platinib should be taken after meals to avoid interactions with food that may affect drug absorption. When starting treatment, patients need to make sure to follow the doctor's instructions, take the medicine on time and in the right amount, and avoid missing doses or changing the dosage at will to ensure the best efficacy of the medicine.

During treatment, patients may require dosage adjustments based on their clinical response and tolerability. If serious adverse reactions occur, the drug may need to be temporarily discontinued or the dose reduced. The dose of platinib may need to be adjusted in patients with mild to moderate hepatic impairment. Under normal circumstances, doctors will regularly monitor the patient's liver function and other related indicators, and adjust the dosage according to the patient's specific condition.

During the treatment of platinib, patients need to undergo regular clinical examination and monitoring, especially the evaluation of liver function, blood routine and tumor markers. Based on the patient's condition and response to treatment, the doctor will decide whether to continue using the drug or make dosage adjustments. In short, the specific usage and dosage of platinib should be individually adjusted according to the patient's specific condition, tolerance and doctor's guidance to achieve the best therapeutic effect.

Reference materials:https://gavreto.com/